Efruxifermin (formerly AKR-001), a long-acting FGF-21 analogue, has shown efficacy in phase 2b trials for nonalcoholic steatohepatitis (NASH) with moderate fibrosis (F2/F3), achieving histologic resolution and fibrosis reduction over 24 weeks [66]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.